Nursing care for chimeric antigen receptor T cell therapy survivors: A literature review

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-06-01 DOI:10.1016/j.apjon.2024.100495

Mercedes Montoro-Lorite, Cristina Moreno, Carla Ramos, María Teresa Solano, Silvia Lahoz, Carolina Bonilla-Serrano, Ariadna Domènech, Pilar Ayora

{"title":"Nursing care for chimeric antigen receptor T cell therapy survivors: A literature review","authors":"Mercedes Montoro-Lorite, Cristina Moreno, Carla Ramos, María Teresa Solano, Silvia Lahoz, Carolina Bonilla-Serrano, Ariadna Domènech, Pilar Ayora","doi":"10.1016/j.apjon.2024.100495","DOIUrl":null,"url":null,"abstract":"<div><p>Chimeric antigen receptor T cell (CAR-T) therapy is an immunotherapy that involves genetically modifying the patient's own T cells to express a chimeric antigen receptor, enabling them to recognize and destroy cancer cells. This treatment has revolutionized the prognosis and management of hematological malignancies, leading to a significant increase in long-term survivors. However, there is limited evidence regarding late sequelae and post-treatment care due to the recent emergence of this therapy. The rapid advancement of CAR-T therapies has created opportunities for advanced practice nurses to play a crucial role in coordinating care, providing education, and ensuring the ongoing well-being of survivors. This article provides an overview of the physical, psychosocial, and financial challenges faced by long-term survivors of CAR-T therapy and proposes a comprehensive nursing care plan to address these issues.</p></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S234756252400115X/pdfft?md5=5de5ad9a32479facbbb20894a544f7d8&pid=1-s2.0-S234756252400115X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S234756252400115X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Chimeric antigen receptor T cell (CAR-T) therapy is an immunotherapy that involves genetically modifying the patient's own T cells to express a chimeric antigen receptor, enabling them to recognize and destroy cancer cells. This treatment has revolutionized the prognosis and management of hematological malignancies, leading to a significant increase in long-term survivors. However, there is limited evidence regarding late sequelae and post-treatment care due to the recent emergence of this therapy. The rapid advancement of CAR-T therapies has created opportunities for advanced practice nurses to play a crucial role in coordinating care, providing education, and ensuring the ongoing well-being of survivors. This article provides an overview of the physical, psychosocial, and financial challenges faced by long-term survivors of CAR-T therapy and proposes a comprehensive nursing care plan to address these issues.

查看原文本刊更多论文

CAR-T 细胞疗法幸存者的护理：文献综述

嵌合抗原受体 T 细胞（CAR-T）疗法是一种免疫疗法，它通过基因修饰患者自身的 T 细胞，使其表达嵌合抗原受体，从而使其能够识别并消灭癌细胞。这种疗法彻底改变了血液恶性肿瘤的预后和治疗，使长期存活者显著增加。然而，由于这种疗法刚刚兴起，有关晚期后遗症和治疗后护理的证据还很有限。CAR-T 疗法的快速发展为高级执业护士创造了机会，使其在协调护理、提供教育和确保幸存者持续健康方面发挥重要作用。本文概述了 CAR-T 疗法长期幸存者所面临的身体、社会心理和经济挑战，并提出了解决这些问题的综合护理计划。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464